Stefanos Theoharis
CEO OneChain Immunotherapeutics
Stefanos, CEO of OneChain Immunotherapeutics, the leading CAR-T company in Spain, brings over 20 years of broad experience in the cell and gene therapy space, BD, program management, manufacturing, and basic research. Prior to that he was Venture Partner at Albion VC and Deep Science Ventures, in London. Formerly, CBO of Bone Therapeutics, developing specialized cell therapies for orthopaedic disorders, SVP, BD at Cell Medica, and CBO at apceth GmbH. He also held positions as and Director of BD at Roche, focused on partnering in emerging science and technologies, and Lazard, the global investment bank.
Seminars
Wednesday 25th February 2026
Industry Leaders Fireside Chat: Navigating Europe’s Cell Therapy Landscape Amid Investment Pressures, Novel Approaches, & Opportunities for Patient Access
8:30 am
- Discuss how investment headwinds are shaping company strategies and what it takes to sustain progress in Europe
- Highlight the most promising scientific advances, including novel indications, armouring strategies, and in-vivo approaches
- Explore how patient access models, from point-of-care manufacturing to evolving reimbursement pathways, can unlock future growth
Wednesday 25th February 2026
Advancing CAR-T Therapies with Real-World Clinical Data to Drive Next- Generation Development
4:15 pm
- Share up-to-date clinical data from the ongoing CAR-T program in T-cell leukaemia
- Discuss the latest development from OneChain’s next-generation CAR-T products across hematologic malignancies and solid tumours
- Explore advantages and opportunities with OneChain’s allogeneic iPSC-derived gamma delta T-cell platform
New Data
